Trial Profile
A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf-06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2020
Price :
$35
*
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Pfizer
- 14 Feb 2020 Results published in the International Journal of Neuropsychopharmacology
- 03 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 27 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016.